Scope
NICE guideline NG208 covers the investigation and management of heart valve disease presenting in adults. It addresses when to request echocardiography or urgent specialist assessment, and which patients to refer after echocardiography. It also covers counselling and referral for pregnant women and women considering pregnancy, and pharmacological management of heart failure. The guideline sets echocardiographic and biomarker thresholds for considering intervention in asymptomatic aortic stenosis, aortic regurgitation and primary mitral regurgitation. It describes surveillance when intervention is not yet needed. It addresses surgical and transcatheter options for aortic stenosis and other aortic valve disease, mitral stenosis and mitral regurgitation, and concomitant surgical repair for tricuspid regurgitation. Further sections cover repeat intervention for degenerated bioprostheses, antithrombotic therapy, monitoring after intervention, and patient information. Recommendation strength is preserved as written: 'offer' and 'consider' are used as in the source.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Echocardiography, specialist referral and pregnancy
- In adults with an isolated murmur and no other signs or symptoms, consider echocardiography when valve disease is suspected. Suspicion may arise from the character of the murmur, family history, age (particularly above 75) or medical history such as atrial fibrillation. [1]
- Offer echocardiography to adults with a murmur and suspected valve disease in two situations. The first is when they also have signs (such as peripheral oedema), symptoms (such as angina or breathlessness) or an abnormal ECG. The second is an ejection systolic murmur with a reduced second heart sound, even without other features. [1]
- When valve disease is suspected, offer urgent specialist assessment including echocardiography (within 2 weeks) to adults with a systolic murmur and exertional syncope. If specialist assessment is unavailable, an urgent echocardiogram alone is acceptable for this group. For adults with a murmur and severe symptoms attributed to valve disease, meaning angina or breathlessness at rest or on minimal exertion, consider urgent (within 2 weeks) specialist assessment that includes echocardiography. [1]
- Mild valve disease is common and seldom becomes clinically significant. After echocardiography, offer specialist referral for moderate or severe disease of any valve type, and for bicuspid aortic valve disease of any severity, including mild. [1]
- Most women with valve disease can have an uncomplicated pregnancy. Offer women needing valve intervention advice on how treatment choices affect future pregnancy. Offer family planning advice to women with severe disease, especially aortic or mitral stenosis. For women of childbearing potential facing valve replacement, consider specialist advice on the choice of valve. [1]
- Refer pregnant women, or women considering pregnancy, to a cardiologist experienced in caring for pregnant women if they have any of the following, whether or not they have symptoms: moderate or severe valve disease, bicuspid aortic valve disease of any severity with associated aortopathy, or a prosthetic valve. [1]
Medical therapy and indications for intervention
- Consider a beta-blocker for adults with moderate to severe mitral stenosis and heart failure. When valve disease and heart failure coexist with left ventricular dysfunction, follow the NICE chronic heart failure guideline. [1]
- Offer intervention to adults with symptomatic severe valve disease. Severity is graded according to British Society of Echocardiography guidance. [1]
- In asymptomatic severe aortic stenosis, consider referral for intervention, if suitable, when any of the following is present: echocardiographic Vmax above 5 m/s; aortic valve area below 0.6 cm2; LVEF below 55%; BNP or NT-proBNP more than twice the upper limit of normal; or symptoms revealed by exercise testing. [1]
- In symptomatic low-gradient aortic stenosis with LVEF below 50%, consider referral for intervention if dobutamine stress echocardiography confirms severe disease. Severe disease is shown by a mean gradient rising above 40 mmHg while the valve area stays below 1 cm2. [1]
- Consider a cardiac CT aortic valve calcium score when the severity of symptomatic aortic stenosis is uncertain. If cardiac MRI shows mid-wall fibrosis in severe aortic stenosis, offer closer follow-up and further assessment, such as stress echocardiography, to judge the need for intervention. [1]
- In asymptomatic severe aortic regurgitation, consider referral for intervention, if suitable, when LVEF is below 55%. Referral should also be considered when echocardiographic end-systolic diameter exceeds 50 mm or its index exceeds 24 mm/m2. [1]
- In asymptomatic severe primary mitral regurgitation, consider referral for intervention, if suitable, when any of the following applies: LVEF below 60%; ESD above 45 mm or ESDI above 22 mm/m2; or exercise-induced systolic pulmonary artery pressure above 60 mmHg. Surgical referral decisions should weigh repairability, atrial fibrillation, and resting pulmonary artery systolic pressure above 50 mmHg. [1]
Surveillance before and after intervention
- Offer clinical review with echocardiography every 6 to 12 months to adults with asymptomatic severe disease who are suitable for intervention but do not yet need it. Set the interval using echo findings and shared decision making. Consider echocardiography every 3 to 5 years for mild aortic or mitral stenosis. [1]
- After valve repair or replacement, tailor the frequency and type of monitoring to several factors. These include the durability of the prosthesis or repair, other conditions including other heart disease, residual abnormalities such as paravalvular leak, concerns about abnormal prosthetic valve function, and patient wishes. Advise patients and carers to seek advice if the condition worsens. [1]
Choice of intervention
- Discuss the benefits and risks of intervention with eligible patients. Cover short- and long-term quality-of-life benefits, prosthetic durability, procedural risks, the access route (median sternotomy, minimally invasive surgery or, for people at high surgical risk, transcatheter access), and possible future cardiac procedures. If minimally invasive surgery is chosen but not available locally, refer to another centre. [1]
- For severe aortic stenosis, regurgitation or mixed aortic disease with a surgical indication, offer surgery, if suitable, as first-line treatment at low or intermediate surgical risk. TAVI is not cost effective in these groups at current list price. Offer TAVI, if suitable, for non-bicuspid severe aortic stenosis at high surgical risk or when surgery is unsuitable. Surgical risk is defined by EuroSCORE II: low below 4%, intermediate 4% to 8%, high above 8%. [1]
- For severe rheumatic mitral stenosis, consider transcatheter valvotomy when the valve is suitable. Offer surgical valve replacement if valvotomy is unsuitable. [1]
- In severe primary mitral regurgitation, offer surgical repair when indicated and surgery is suitable. Offer replacement instead if the valve cannot be repaired. Consider transcatheter edge-to-edge repair, if suitable, for symptomatic patients in whom surgery is unsuitable. [1]
- In severe secondary mitral regurgitation, consider surgical repair, or replacement if the valve is not repairable, in patients already undergoing cardiac surgery for another reason. Where surgery is unsuitable and heart failure is present, offer medical management. Consider transcatheter edge-to-edge repair if symptoms persist despite medical management. [1]
- Consider concomitant surgical tricuspid repair during mitral valve surgery when tricuspid regurgitation is moderate or severe. Consider it during aortic valve surgery when tricuspid regurgitation is severe. [1]
- For symptomatic severe degeneration of an aortic biological prosthesis, consider either transcatheter or redo surgical intervention. Reach a shared decision on the choice of intervention by weighing short- and long-term benefits, the type of dysfunction and prosthesis, procedural risks, and the possible need for future cardiac procedures. Degeneration excludes failure due to endocarditis or thrombosis. [1]
Antithrombotic therapy and patient information
- Do not offer anticoagulation after surgical biological valve replacement unless another indication exists. After TAVI, consider aspirin, or clopidogrel if aspirin is not tolerated. For other anticoagulant or antiplatelet indications, follow the NICE atrial fibrillation and acute coronary syndrome guidelines. [1]
- Recognise the psychological impact of a valve disease diagnosis, even when asymptomatic. Consider offering a point of contact for specialist advice between appointments. Give information on expected progression and prognosis, including the likely length of the asymptomatic phase, and on palliative care where appropriate. [1]
Limitations and use
- Applies to adults presenting with heart valve disease; paediatric care is not covered beyond information about transition to adult services.
- Research recommendations, rationale and impact sections, and committee discussion were not part of the reviewed source.
- Several topics are delegated to other NICE guidance and are not summarised here: non-exertional syncope, breathlessness without murmur, chronic heart failure, intrapartum care, TAVI and other interventional procedures guidance, atrial fibrillation, and acute coronary syndromes.
- Valve severity grading relies on British Society of Echocardiography criteria, which are not reproduced in the source.
- The NHS England position on TAVI for patients at low or intermediate surgical risk is referenced but not included.
- Flowcharts and visual algorithms were available only as alternative text.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Heart valve disease presenting in adults: investigation and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 17 November 2021
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.